SCHEMBL532147

SCHEMBL532147

CN1CCN(C(=O)c2ccc(B(O)O)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.65
HPGD P15428 6/20 0.61
ALOX15 P16050 1/20 0.61
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C19 P33261 1/20 0.58
GRM5 P41594 1/20 0.56
TSHR P16473 1/20 0.54
HRH3 Q9Y5N1 2/20 0.54
LMNA P02545 1/20 0.54
EPHX2 P34913 2/20 0.52
NPC1 O15118 1/20 0.52
L3MBTL3 Q96JM7 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2550272 0.98 POLB (0.63) POLBHPGDALOX15KMT2AMEN1
SCHEMBL7010051 0.94 POLB (0.59) POLBHPGDALOX15KMT2AMEN1
SCHEMBL29253633 0.92 HPGD (0.61) POLBHPGDALOX15KMT2AMEN1
SCHEMBL29950978 0.91 HPGD (0.57) POLBHPGDALOX15KMT2AMEN1
SCHEMBL10724841 0.87 POLB (0.81) POLBHPGDALOX15KMT2AMEN1
SCHEMBL950365 0.84 HPGD (0.64) POLBHPGDKMT2AMEN1TSHR
SCHEMBL204078 0.84 HPGD (0.70) HPGDKMT2AMEN1TSHRLMNA
SCHEMBL12543946 0.83 ALDH1A1 (0.52) POLBKMT2AMEN1
SCHEMBL258027 0.82 HPGD (0.74) HPGDKMT2AMEN1TSHRLMNA
SCHEMBL3655722 0.82 CHRNA7 (0.61) KMT2AMEN1HRH3LMNAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132140-A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS BENEVOLENTAI BIO LTD (GB) 2026-05-14 US disclosed
EP-4590671-A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS BenevolentAI Bio Limited (GB) 2025-07-30 EP disclosed
WO-2025086243-A1 LEUKOCYTE RECEPTOR TYROSINE KINASE INHIBITOR 深圳湾实验室坪山生物医药研发转化中心 2025-05-01 WO disclosed
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 US disclosed
WO-2024088379-A1 TUMOR TREATMENT OR PREVENTION METHOD 香港科技大学 2024-05-02 WO disclosed
WO-2024088377-A1 PYRIMIDOPYRROLE ANALOG 香港科技大学 2024-05-02 WO disclosed
WO-2024062250-A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS BENEVOLENTAI BIO LIMITED (GB) 2024-03-28 WO disclosed
CN-110172051-B IRE-1 alpha inhibitors 复星弘创(苏州)医药科技有限公司 2023-03-07 CN disclosed
US-20230009626-A1 INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS ICHNOS SCIENCES S.A. (CH) 2023-01-12 US disclosed
US-20230009626-A1 INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS ICHNOS SCIENCES S.A. (CH) 2023-01-12 US disclosed
WO-2007124254-A2 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed
US-20050113402-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors SUI ZHIHUA (US) 2005-05-26 US disclosed
US-6818646-B2 1,2,3,4-TETRAHYDRO-2-(5-(2-PYRIDINYL)-PYRIMIDIN-2-YL)-3-(2,3 -DIHYDROBENZOFURANYL)-9H-PYRROLO-(3,4-B)QUINOLIN-9-ONE; MALE ERECTILE DYSFUNCTION; SEXUAL DISORDERS SUI ZHIHUA (US) 2004-11-16 US disclosed
EP-1296981-B1 SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS ORTHO MCNEIL PHARM INC (US) 2004-10-06 EP disclosed
US-20040044021-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors SUI ZHIHUA (US) 2004-03-04 US disclosed
US-6635638-B2 Treatment of sexual dysfunction, cardiovascular system disorders ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-10-21 US disclosed
EP-1296981-A2 SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS Ortho-McNeil Pharmaceutical, Inc. (US) 2003-04-02 EP disclosed
US-20020010183-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-01-24 US disclosed
WO-2001087882-A2 SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113402-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors PDE5A, PDE3A, PDE3B POLB 506/4885HPGD 45/4885ALOX15 1960/4885
US-20260132140-A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS CHEK1, CHEK2, BUB1 POLB 1719/4885HPGD 3219/4885ALOX15 4848/4885
US-20040044021-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors PDE5A, PDE3A, PDE3B POLB 580/4885HPGD 52/4885ALOX15 2043/4885
US-20020010183-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors PDE5A, PDE3A, PDE3B POLB 580/4885HPGD 52/4885ALOX15 2043/4885
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R POLB 4403/4885HPGD 2557/4885ALOX15 1873/4885
US-20230009626-A1 INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS MAP4K1, MAP4K2, MAP4K4 POLB 3665/4885HPGD 1544/4885ALOX15 4095/4885
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 POLB 2343/4885HPGD 438/4885ALOX15 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.